270 related articles for article (PubMed ID: 10880372)
41. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma.
Amara N; Palapattu GS; Schrage M; Gu Z; Thomas GV; Dorey F; Said J; Reiter RE
Cancer Res; 2001 Jun; 61(12):4660-5. PubMed ID: 11406532
[TBL] [Abstract][Full Text] [Related]
42. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder.
Shirahama T
Clin Cancer Res; 2000 Jun; 6(6):2424-30. PubMed ID: 10873095
[TBL] [Abstract][Full Text] [Related]
43. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
44. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
45. Down-regulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression.
Korabiowska M; Quentin T; Schlott T; Bauer H; Kunze E
World J Urol; 2004 Dec; 22(6):431-40. PubMed ID: 15551138
[TBL] [Abstract][Full Text] [Related]
46. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
[TBL] [Abstract][Full Text] [Related]
47. Coexistent intraurothelial carcinoma and muscle-invasive urothelial carcinoma of the bladder: clonality and somatic down-regulation of DNA mismatch repair.
Blanes A; Rubio J; Sanchez-Carrillo JJ; Diaz-Cano SJ
Hum Pathol; 2009 Jul; 40(7):988-97. PubMed ID: 19368958
[TBL] [Abstract][Full Text] [Related]
48. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors.
Yoshimura R; Matsuyama M; Tsuchida K; Kawahito Y; Sano H; Nakatani T
J Urol; 2003 Nov; 170(5):1994-9. PubMed ID: 14532840
[TBL] [Abstract][Full Text] [Related]
49. Inducing cell proliferation inhibition and apoptosis via silencing Dicer, Drosha, and Exportin 5 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Gui Y; Cai Z
J Surg Oncol; 2013 Feb; 107(2):201-5. PubMed ID: 22766726
[TBL] [Abstract][Full Text] [Related]
50. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
[TBL] [Abstract][Full Text] [Related]
51. [Expression of cyclooxygenase-2 in bladder transitional cell carcinoma and the significance thereof].
Yu L; Chen XJ; Shi PQ; Ding Q; Sun CH; Liu GB; Shi DM; Huang YG
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2683-4. PubMed ID: 19080686
[TBL] [Abstract][Full Text] [Related]
52. IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
Yang F; Zhou Q; Meng L; Xing N
Medicine (Baltimore); 2019 Jul; 98(27):e16009. PubMed ID: 31277094
[TBL] [Abstract][Full Text] [Related]
53. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of deleted in malignant brain tumors 1 (DMBT1) gene expression in bladder carcinoma cases: preliminary study.
Dodurga Y; Avci CB; Yilmaz S; Dogan ZO; Kesen Z; Tataroglu C; Satiroglu-Tufan NL; Bushra T; Gunduz C
Biomarkers; 2011 Nov; 16(7):610-5. PubMed ID: 21999583
[TBL] [Abstract][Full Text] [Related]
55. Progressive loss of CD44 gene expression in invasive bladder cancer.
Sugino T; Gorham H; Yoshida K; Bolodeoku J; Nargund V; Cranston D; Goodison S; Tarin D
Am J Pathol; 1996 Sep; 149(3):873-82. PubMed ID: 8780391
[TBL] [Abstract][Full Text] [Related]
56. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
57. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
58. Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer.
Mokos I; Jakić-Razumović J; Mareković Z; Pasini J
Tumori; 2006; 92(2):124-9. PubMed ID: 16724691
[TBL] [Abstract][Full Text] [Related]
59. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
60. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
